CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis

Xiaojie Zhao, Xin Yu, Wen Ge Li, Zhiyuan Chen, Tingting Niu, Xiaodong Weng, Lei Wang, Xiuheng LiuInternational Journal of Medical Sciences 2024 · DOI

TL;DR

This study identifies Cyclin-Dependent Kinase 6 (CDK6) as a crucial biomarker in bladder cancer, linking its high expression to poorer prognosis and reduced response to immunotherapy. The research suggests that targeting CDK6 could be a promising strategy to improve treatment outcomes for bladder cancer patients.

What Problem Does This Paper Address?

Bladder cancer (BLCA) is a significant health concern, being the second most common urinary system tumor. While advancements in treatment have improved survival rates, a substantial portion of patients still experience resistance to immunotherapies, highlighting the need for better prognostic markers and therapeutic targets. The role of CDK6, a known regulator of cell cycle and transcription, in BLCA's progression, metastasis, and its impact on the tumor microenvironment and treatment response, has remained unclear. This paper aims to elucidate CDK6's molecular mechanisms and its prognostic value in BLCA to inform personalized treatment strategies.

Methods

The researchers employed a multi-pronged approach combining bioinformatics analysis with immunohistochemistry (IHC).

  • Bioinformatics Analysis: They utilized public databases (TCGA, IMvigor210 CoreBiologies) to analyze gene expression, mutation data, and clinical information from large cohorts of bladder cancer patients. Techniques included:
  • Kaplan-Meier analysis and Cox regression: To assess the prognostic value of CDK6 expression and identify significant clinical factors.
  • Differential Gene Expression (DEG) analysis: Using the Limma R package to identify genes whose expression levels change significantly between high and low CDK6 expression groups.
  • Functional Enrichment Analysis: Employing the ClusterProfiler package for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to understand the biological functions of DEGs.
  • Molecular Subtyping: Using ConsensusMIBC R packages to classify BLCA subtypes.
  • Immune Cell Infiltration Analysis: Utilizing the CIBERSORT R package to quantify the abundance of various immune cell types within the tumor microenvironment.
  • Chemotherapy Reaction Forecast: Using the "pRRophetic" R package to predict drug sensitivity.
  • Immunohistochemistry (IHC): A single-center retrospective cohort (Cohort 2) was used to validate CDK6 protein expression in BLCA tissues. Standard IHC protocols were followed, and a scoring system was developed to quantify protein staining intensity and percentage.

Datasets

The study utilized data from three main cohorts:

  • Cohort 1 (TCGA-BLCA): Gene expression, mutation, and clinical data from 408 bladder cancer samples from The Cancer Genome Atlas.
  • Cohort 2 (Single-center retrospective): Formalin-fixed paraffin-embedded specimens from 100 bladder cancer patients collected at Renmin Hospital of Wuhan University. This cohort was used for IHC validation.
  • Cohort 3 (IMvigor210): Immunotherapy-related data, including expression and clinical information from 348 bladder cancer patients, obtained via the IMvigor210 CoreBiologies dataset.

Key Insights and Ideas

  • CDK6 as a Prognostic Indicator: High CDK6 expression is a strong indicator of poor prognosis in bladder cancer, correlating with advanced stages and reduced overall survival. This suggests CDK6 is not just a marker of progression but actively contributes to a worse clinical outcome.
  • CDK6 and Immunotherapy Resistance: A critical finding is that patients with high CDK6 expression respond poorly to immunotherapy. This is a significant clinical implication, as it points to a mechanism by which tumors can evade immune surveillance.
  • CDK6's Role in Immune Suppression: The study reveals that CDK6 actively suppresses the tumor immune microenvironment. It appears to orchestrate a complex interplay of immune cell infiltration and signaling pathways that ultimately dampen anti-tumor immune responses.
  • Molecular Subtype Association: High CDK6 expression is particularly prevalent in the "basal" molecular subtype of bladder cancer, which is often associated with more aggressive disease. This provides a link between molecular classification and prognostic markers.
  • Therapeutic Target Potential: The findings strongly suggest that targeting CDK6, either alone or in combination with existing therapies like immunotherapy, could be a viable strategy to overcome treatment resistance and improve patient outcomes.

Key Results

  • Prognostic Value: In pan-cancer analysis, high CDK6 expression was linked to worse overall survival in several cancer types, including BLCA. In BLCA-specific analyses, high CDK6 expression was consistently associated with poorer prognosis and shorter recurrence-free survival.
  • Immunotherapy Response: Patients with high CDK6 expression showed significantly poorer responses to immunotherapy, as evidenced by lower response rates and shorter progression-free survival.
  • Molecular Mechanisms: High CDK6 expression was associated with 2093 upregulated and 1306 downregulated differentially expressed genes (DEGs). Functional analysis revealed enrichment in pathways related to immune system processes, cytokine-cytokine receptor interactions, and the PI3K-Akt signaling pathway. Downregulated DEGs were linked to lipid metabolism and xenobiotic metabolism.
  • Immune Microenvironment: High CDK6 expression was correlated with increased infiltration of certain immune cells (e.g., macrophages) but also with signs of immune exhaustion, including reduced infiltration of cytotoxic T cells and impaired immune cell activation.
  • Treatment Sensitivity: High CDK6 expression was associated with resistance to gemcitabine and cisplatin, common chemotherapeutic agents. Conversely, it was linked to sensitivity to certain targeted therapies, including tyrosine kinase inhibitors.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Bias: The use of samples from a single clinical center in Cohort 2 may introduce sample bias.
  • Retrospective Design: The retrospective nature of the study introduces potential confounding factors and limits the ability to establish causality.
  • In Vivo/In Vitro Validation: The study relies heavily on bioinformatics and retrospective data. Further validation through in vivo and in vitro experiments is necessary to precisely ascertain CDK6's function and mechanisms.

Future work should focus on:

  • Precise Functional Mechanisms: Deeper investigation into the specific molecular mechanisms by which CDK6 influences tumor progression, immune evasion, and treatment response.
  • Clinical Trial Design: Designing prospective studies and clinical trials to validate CDK6 as a biomarker and to evaluate the efficacy of CDK6-targeting therapies, particularly in combination with immunotherapies.
  • Broader Patient Populations: Expanding validation to larger and more diverse patient cohorts to confirm the generalizability of these findings.

Summary updated

Abstract

Background: CDK6 is linked to tumor progression and metastasis, although its molecular mechanism and prognostic value are unclear in bladder cancer. Materials and methods: In our study, raw data were obtained from public databases and Single-center retrospective case series. We conducted a bioinformatics analysis and immunohistochemistry to explore the biological landscape of CDK6 in tumors, with a particular focus on bladder cancer. We examined its expression characteristics and prognostic value and performed functional annotation analysis using gene function enrichment. We also assessed the association between bladder cancer molecular subtypes and mutation spectra and analyzed the landscape of the tumor immune microenvironment to predict treatment response sensitivity. Results: Our study found that CDK6 was a potential prognostic marker for bladder cancer. We discovered that bladder cancer patients with high CDK6 expression do not respond well to immunotherapy and have a poor prognosis. CDK6 regulates tumor immune status, metabolism, and cell cycle-related signaling pathways, thereby influencing tumor biological behavior. Furthermore, CDK6 mediated the suppression of the immune microenvironment to weaken anti-tumor immune responses. Finally, a comprehensive characterization of CDK6 was applied in the prognostic prediction of bladder cancer, suggesting that targeting CDK6 represents a potential therapeutic option. Conclusions: These results indicated that CDK6 is an independent biomarker for predicting prognosis and immunotherapy efficacy of bladder cancer. A deeper understanding of its specific molecular mechanisms may provide new treatment strategies.
BibTeX
@article{zhao2024cdk,
  author = {Xiaojie Zhao and Xin Yu and Wen Ge Li and Zhiyuan Chen and Tingting Niu and Xiaodong Weng and Lei Wang and Xiuheng Liu},
  title = {{CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis}},
  journal = {International Journal of Medical Sciences},
  year = {2024},
  doi = {10.7150/ijms.101043},
}
Figure